U.K. Panel Says: Continue DES Use, But Limit Price Premium Over Bare Metal
This article was originally published in The Gray Sheet
Executive Summary
The United Kingdom's National Institute of Health and Clinical Excellence has retreated from its August 2007 recommendation that the country's National Health Service stop paying for drug-eluting stents after being bombarded with criticism from interventional cardiologists and stent manufacturers
You may also be interested in...
Washington State Chief Medical Officer Touts Cost Effectiveness
As the debate over what role cost-effectiveness research should play in health reform continues on a national level, some states have already made cost comparisons a routine part of the policy making process
Washington State Chief Medical Officer Touts Cost Effectiveness
As the debate over what role cost-effectiveness research should play in health reform continues on a national level, some states have already made cost comparisons a routine part of the policy making process
NICE denies Cordis appeal
The United Kingdom's National Institute for Health and Clinical Excellence denies Johnson & Johnson/Cordis' appeal of its Feb. 1 recommendation that the National Health Service only cover drug-eluting coronary stents if the device costs no more than £300 ($597) more than a comparable bare-metal stent (1"The Gray Sheet" Feb. 4, 2008, p. 10). 2In a decision released July 23, NICE's appeals panel, which met in April, discounts Cordis' arguments, concluding that NICE's recommendation does not exceed its legal powers or violate its established procedures and is consistent with the scientific evidence. There is no possibility of further appeal within NICE, but interested parties can seek permission form the High Court to apply for judicial review within three months, the panel writes. The denial of the appeal coincides with NICE's re-release of its 3final guidance on drug-eluting coronary stents outlining its recommendations